When a patient is diagnosed with head and neck cancer, doctors look for any signs that can help predict how the disease will progress. A new look at data from 1,759 patients suggests that a specific blood measurement called the HALP score could provide that clarity. This score combines levels of hemoglobin, albumin, lymphocytes, and platelets to give a snapshot of a patient's health.
The analysis found that patients with a higher HALP score before starting treatment had better overall survival rates. It also showed that these patients had better disease-free survival, meaning the cancer stayed away for longer periods. These results remained consistent even when looking specifically at patients whose cancer had not yet spread to other parts of the body.
While this score is a helpful tool for doctors to evaluate a patient's outlook, there are still some hurdles. Different studies used different cutoff points to decide what a "high" score actually was. Because this was an observational analysis and not a clinical trial, it shows a link between the score and survival rather than a direct cause. It is a helpful piece of the puzzle for doctors managing head and neck cancer.
